SIGHT Overview

Financial Results Overview: GenSight Biologics reported estimated consolidated financial results for 2024, showing a significant reduction in operational losses from €29.7 million in 2023 to €15.8 million in 2024, alongside a net loss decrease from €26.2 million to €14 million.

Future Outlook and Challenges: The company is focusing on securing financing to extend its cash runway beyond April 2025, while addressing regulatory inquiries regarding its LUMEVOQ® program and preparing for potential funding needs before the second half of 2026.

Financial Performance Overview: GenSight Biologics reported a significant reduction in net loss for FY 2024, amounting to €14 million compared to €26.2 million in FY 2023, alongside a decrease in operating expenses and improved cash management strategies.

Future Outlook and Challenges: The company anticipates potential liquidity risks and is exploring bridge financing options while awaiting regulatory approvals for its compassionate access program, which is crucial for extending its cash runway beyond the next 12 months.

Study Results: GenSight Biologics announced positive results from a 5-year follow-up of their Phase III REFLECT study on LUMEVOQ (lenadogene nolparvovec), showing sustained improvement in visual acuity for patients with Leber Hereditary Optic Neuropathy (LHON) after a single gene therapy injection, particularly benefiting those receiving bilateral treatment.

Safety Profile: The safety profile of LUMEVOQ remained favorable, with no serious adverse events reported, and comparable outcomes between patients treated bilaterally and unilaterally, reinforcing the therapy's viability for treating this rare genetic condition.

Clinical Trial Results: GenSight Biologics reported that their gene therapy LUMEVOQ (lenadogene nolparvovec) showed sustained visual acuity improvement in patients with Leber Hereditary Optic Neuropathy (LHON) five years after treatment, with bilateral injections yielding better outcomes than unilateral ones.

Safety Profile: The safety profile of LUMEVOQ remained favorable, with no serious adverse events reported and mild intraocular inflammation being the main ocular side effect, confirming its comparability between bilaterally and unilaterally treated subjects.

Financial Update: GenSight Biologics reported a cash position of €2.5 million as of December 31, 2024, down from €3.4 million in September 2024, and is working on optimizing cash management while awaiting regulatory clearance for its early access program.

Regulatory Progress: The French medicines safety agency ANSM is reviewing the quality dossier for LUMEVOQ®, with preparations ongoing for a new Phase III trial and submission to the UK’s MHRA, while the company anticipates needing additional financing to meet future obligations.

Financial Situation: GenSight Biologics reported a cash position of €2.5 million as of December 31, 2024, down from €3.4 million in September 2024, and is seeking to optimize cash management while awaiting regulatory approval for its compassionate access program.

Regulatory Developments: The French National Agency for the Safety of Medicines (ANSM) is reviewing GenSight's quality dossier for LUMEVOQ, with preparations underway for a new Phase III clinical trial and submission to the UK regulatory agency MHRA.